# Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

> **NCT03773367** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lund University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03773367
- **Lead sponsor:** Lund University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-14
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03773367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03773367, "Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03773367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*